Xenon Pharmaceuticals Valuation

XENE Stock  USD 40.47  0.28  0.70%   
At this time, the company appears to be fairly valued. Xenon Pharmaceuticals maintains a prevalent Real Value of $41.21 per share. The last-minute price of the company is $40.47. Our model calculates the value of Xenon Pharmaceuticals from examining the company fundamentals such as Current Valuation of 2.44 B, return on asset of -0.19, and Shares Owned By Insiders of 0.37 % as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
40.47
Please note that Xenon Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Xenon Pharmaceuticals is based on 3 months time horizon. Increasing Xenon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Xenon stock is determined by what a typical buyer is willing to pay for full or partial control of Xenon Pharmaceuticals. Since Xenon Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xenon Stock. However, Xenon Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  40.47 Real  41.21 Hype  40.47 Naive  40.72
The real value of Xenon Stock, also known as its intrinsic value, is the underlying worth of Xenon Pharmaceuticals Company, which is reflected in its stock price. It is based on Xenon Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Xenon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
41.20
Real Value
43.52
Upside
Estimating the potential upside or downside of Xenon Pharmaceuticals helps investors to forecast how Xenon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xenon Pharmaceuticals more accurately as focusing exclusively on Xenon Pharmaceuticals' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
38.1639.6541.14
Details
Hype
Prediction
LowEstimatedHigh
38.1640.4742.78
Details
Naive
Forecast
LowNext ValueHigh
38.4140.7243.03
Details

Xenon Pharmaceuticals Total Value Analysis

Xenon Pharmaceuticals is at this time estimated to have valuation of 2.44 B with market capitalization of 3.09 B, debt of 10.9 M, and cash on hands of 788.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Xenon Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
2.44 B
3.09 B
10.9 M
788.24 M

Xenon Pharmaceuticals Asset Utilization

One of the ways to look at asset utilization of Xenon is to check how much profit was generated for every dollar of assets it reports. Xenon Pharmaceuticals maintains a negative usage of resources of -0.19 (%), losing $0.001892 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it maintains. Specifically, asset utilization of Xenon Pharmaceuticals shows how discouraging it operates for each dollar spent on its resources.

Xenon Pharmaceuticals Ownership Allocation

The majority of Xenon Pharmaceuticals outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Xenon Pharmaceuticals to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Xenon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Xenon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.

Xenon Pharmaceuticals Profitability Analysis

Net Loss for the year was (182.39 M) with loss before overhead, payroll, taxes, and interest of (177.91 M).
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Xenon Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Xenon Pharmaceuticals and how it compares across the competition.

About Xenon Pharmaceuticals Valuation

The stock valuation mechanism determines Xenon Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Xenon Pharmaceuticals. We calculate exposure to Xenon Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Xenon Pharmaceuticals's related companies.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.

Xenon Pharmaceuticals Growth Indicators

Investing in growth stocks can be very risky. If the company such as Xenon Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding66.9 M

Complementary Tools for Xenon Stock analysis

When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm